

Technology Advisory Committee A Interests Register
Andexanet alfa for reversing anticoagulation [ID1101]
Publication Date: 12/05/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Steve Edwards	TAC Committee Member	Non-financial professional & personal interest	Member of the relevant Evidence Review Group for this appraisal	NA	04/03/2020	NA	It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
Dr Deepa Jayakody Arachchillage	Clinical expert	Indirect interest	Gave an expert lecture in a meeting supported by Portola Pharmaceuticals. There was no direct contact with Portola Pharmaceuticals as the invitation to the lecture came from PCM scientific.	NA	24/12/2019	NA	It was agreed that this declaration would not prevent Dr Arachchillage from providing expert advice to the committee.
Mr Diederik Bulters	Clinical expert	Direct financial interest	Received a consultancy fee in 2016 for providing expert opinion and feedback to Portola Pharmaceuticals on Andexanet alfa.	NA	01/02/2021	NA	It was agreed that this declaration would not prevent Mr Bulters from providing expert advice to the committee.

<p>Professor Elizabeth Warburton</p>	<p>Clinical expert</p>	<p>Non-financial professional & personal interest</p>	<p>Local PI on various RCTs:</p> <ul style="list-style-type: none"> • Ongoing Tenecteplase (thrombolysis) trials: ATTEST – Trial Steering group committee and local PI. Have stepped down from both roles for committee. • TASTE and TWIST trials – stepped down from local PI role. UK Thrombectomy trial. • STABILISE – local PI (trial now finished and published) CHARM (cerebral oedema) - stepped down as local PI. • Head positioning after stroke trial HEADPOST – local PI (trial now finished and published). • Blood pressure after stroke trials INTERACT – Local PI (trial finished and published). • ENCHANTED - local PI (no longer recruiting) <p>Participated in the OPTIMAS trial; a British Heart Foundation and Stroke Association funded multicentre trial on the timing of the start of anticoagulants in</p>	<p>NA</p>	<p>17/01/2020</p>	<p>NA</p>	<p>It was agreed that these declarations would not prevent Professor Warburton from providing expert advice to the committee</p>
--------------------------------------	------------------------	---	---	-----------	-------------------	-----------	--

			<p>patients with AF following ischemic stroke.</p> <p>Awarded the Pfizer Pharmaceuticals Grant for innovation in stroke prevention in AF after national competition via the NHS Academic Health Sciences Networks (£250,000 awarded Dec 2016)</p>				
Professor Elizabeth Warburton	Clinical expert	Non-financial professional & personal interest	<p>Topic advisor for the NICE CG Stroke Rehabilitation guidelines committee</p> <p>Board member of the NIHR HTA Clinical Trials Advisory Panel (since 2020)</p> <p>Honorary Treasurer British Association of Stroke Physicians (2020-)</p> <p>Editorial board of the AHA journal Stroke (from 2020).</p>	NA	27/01/2021	NA	It was agreed that these declarations would not prevent Professor Elizabeth Warburton from providing expert advice to the committee.
Mr Patrick Grover	Clinical Expert	Direct financial interest	<p>Participated in two Delphi consensuses for Portola Pharmaceuticals regarding this drug, for which he was received remuneration.</p>	NA	31/01/2021	NA	It was agreed that this declaration would not prevent Mr Grover from providing expert advice to the committee.